Navigation Links
Researchers find new hope for treatment of chronic leukemia

Wednesday, August 17, 2011, Cleveland: While testing a new drug designed to treat chronic leukemia, researchers at Cleveland Clinic discovered new markers that could identify which patients would receive maximum benefit from the treatment.

This information was released in the online edition of Blood, a weekly medical journal published by the American Society of Hematology.

Chronic lymphocytic leukemia (CLL), a cancer of the white blood cells that is incurable with standard treatment, is the most common type of leukemia in the Western Hemisphere. Conventional chemotherapy is effective at controlling CLL for many years, but the disease always relapses. CLL is characterized by an uncontrolled cell growth and division due to a defect in a process called programmed cell death, or apoptosis. A group of proteins called the Bcl-2 family is responsible for this defect.

Alex Almasan, Ph.D., a researcher in the Lerner Research Institute (LRI) of Cleveland Clinic in close collaboration with other researchers in both LRI and the Taussig Cancer Institute of Cleveland Clinic collected blood samples from patients with CLL and tested the ability of a new drug to kill the cancerous cells. The drug, Navitoclax, is already in early stage clinical testing for patients with CLL. Navitoclax appears to be effective for some patients, and until this research study, there had been no clear way to predict who will respond to its effects.

In addition, these studies can be informative to the currently ongoing clinical trials with Navitoclax in other hematologic malignancies or solid tumors.

"Follow-up studies on patients that have been treated with Navitoclax, particularly those that are poor responders, could determine whether the Bcl-2 family genes examined in this study may also be important for development of resistance to this agent," said Almasan.


Contact: Dan Doron
Lerner Research Institute

Page: 1

Related biology news :

1. Researchers find way to align gold nanorods on a large scale
2. UBC researchers discover key mechanism that regulates shape and growth of plants
3. Researchers discover oldest evidence of nails in modern primates
4. Researchers map pathway of infection for a common, potentially life-threatening respiratory virus
5. Researchers demonstrate green tea is effective in treating genetic disorder and types of tumors
6. Researchers discover freshwater mussel species thought to be extinct
7. NYU Langone researchers identify a signaling pathway as possible target for cancer treatment
8. Toronto researchers first to discover new genetic clue in the development of rheumatoid arthritis
9. Researchers decode workings of mysterious, but critical TB drug
10. Researchers fight cholera with computer forecasting
11. Vanderbilt researchers, international team, uncover genes linked to multiple sclerosis
Post Your Comments:
(Date:9/30/2015)... , Sept. 30, 2015  The U.S. Court ... issued another key ruling in favor of Crossmatch ... Korean fingerprint scanner company Suprema and its U.S. partner ... 1930, a trade provision that declares it unlawful to ... by infringing two of Crossmatch,s patents, the 5,900,993 patent ...
(Date:9/29/2015)... , Sept. 29, 2015  iDAvatars is excited to be ... its product to market. The official announcement was recently made ... event in San Francisco , where ... powered by IBM Watson. "It is both an ... 100 companies to bring to market the cognitive power of ...
(Date:9/28/2015)... The global image sensors ... billion by 2020, growing at a CAGR of 4.6% ... Illumination (BSI) technique to improve picture quality are expected ...      (Logo: , The light ... loss and, thus, reduce the noise interference and increase ...
Breaking Biology News(10 mins):
(Date:10/9/2015)... ANNAPOLIS, Md. , Oct. 9, 2015 ... entered into the Congressional Record her statement recognizing the ... celebrated October 11-17. IPAW is sponsored by the ... companies, and is designed to:   , Raise ... contributions of plasma donors in saving and improving lives ...
(Date:10/9/2015)... and ROCKVILLE, Md. , Oct. ... privately-held biotechnology company developing next generation vaccines based ... has entered into an exclusive worldwide licensing agreement ... the treatment or prevention of any and all ... agreement, Immunomic Therapeutics will receive an upfront payment ...
(Date:10/9/2015)... Inc., (NASDAQ: PULM ) will be webcasting the Company,s ... th Annual BIO Investor Forum on Tuesday, October 20, ... --> th Annual BIO Investor Forum on Tuesday, ... --> Pulmatrix will be presenting at the ... October 15, 2015 at 8:30 am EDT. Additionally, the Company ...
(Date:10/9/2015)... ... 09, 2015 , ... Leading microbial genomics startup uBiome today launched the first-ever ... between weight management and the microbiome. The study uses the ResearchKit framework, designed by ... app. , The uBiome app is available as a free download from the App ...
Breaking Biology Technology: